ERBB2 and breast cancer: A recently published study on a large cohort of breast cancer patients (1519 cases) treated with NACT and stratified by molecular subtype (261 TN, 377 HER2-positive, and 881 luminal-HER2-negative) found that pre-treatment NLRhigh was independently associated with a worse OS in TN and HER2-positive breast cancer, but no association was observed in luminal tumors [43].